The Peter MacCallum Cancer Centre, in partnership with GE Healthcare, is leading a new clinical trial evaluating the performance and quality of a next-generation total body PET scanner compared to conventional PET imaging for cancer detection. As of December 2025, this study is listed as ‘Not yet recruiting.’
In this article:
- What changed?
- Why is this clinical trial important?
- What are the next steps?
- FAQ
- Conclusion
- Disclaimer
- Announcement Link
What changed?
This upcoming clinical trial, named EQUIP (Evaluation of Quality of Imaging on a Next-Generation Total Body PET Scan in Comparison to Conventional PET), marks a significant step toward improving cancer imaging technologies. While traditional PET imaging systems provide valuable diagnostic insight, this study endeavors to determine whether new-generation total body PET scanners can enhance imaging quality and diagnostic accuracy. The study is currently not enrolling participants but is expected to recruit soon. Healthcare institutions, regulatory professionals, and clinicians will want to monitor developments from this trial.
Why is this clinical trial important?
Cancer detection often relies on advanced imaging systems like PET scans. These scans work by detecting the metabolic activity of cells, particularly cancerous ones. Conventional PET scanners have long been the standard, but advancements in technology enable the possibility of sharper images, reduced scanning times, and potentially lower radiation exposure for patients.
The trial aims to compare the performance of the new total body PET device to conventional PET scanners in a clinical setting. Outcomes such as image clarity, diagnostic effectiveness, patient comfort, and operational efficiency will be assessed. If successful, this new scanner could pave the way for innovative imaging protocols, benefiting both patients and healthcare providers by potentially accelerating cancer diagnosis and treatment planning.
The Peter MacCallum Cancer Centre, an internationally reputed institute in cancer care, and GE Healthcare, a leader in medical imaging technologies, are spearheading the trial. Their combined expertise in oncology and device innovation ensures that this study meets the highest standards in clinical research.
Recruitment plans
The trial is listed as ‘Not yet recruiting,’ which aligns with the preparation phase to finalize protocols, obtain ethical clearances, and ensure regulatory compliance. Interested stakeholders are encouraged to check for updates on the recruitment process and trial progress on the official ClinicalTrials.gov page linked below.
What are the next steps?
Once recruitment begins, patients diagnosed with cancer may be eligible for participation, depending on specific inclusion criteria. The study’s findings are expected to contribute valuable data for regulatory submissions, including safety and performance analyses, required under medical device regulations, such as MDR Annex XIV or similar standards.
Clinical teams and regulatory agents should consider how this imaging system could influence clinical workflows and compliance with evolving global regulatory frameworks.
FAQ
1. What is a PET scan?
PET, or Positron Emission Tomography, is a medical imaging technique used primarily for diagnosing and monitoring diseases such as cancer by detecting metabolic activity within the body.
2. What makes total body PET imaging different?
Total body PET scanners can image a larger portion or the entirety of the body in a single scan, leading to faster results and potentially improved accuracy.
3. When will participant recruitment begin?
As of now, the trial status is ‘Not yet recruiting.’ Updates will be available on ClinicalTrials.gov and other official channels.
4. What organizations are conducting this study?
The Peter MacCallum Cancer Centre and GE Healthcare are co-sponsoring this trial.
Conclusion
This trial reflects the drive to advance cancer imaging technologies and evaluate them against established systems. Professionals in clinical imaging, oncology, and regulatory fields should follow this project closely. Outcomes could hold significant implications for both clinical protocols and regulatory framework alignment.
Disclaimer
This article is for informational purposes only and is not intended as legal or medical device compliance advice. Always consult regulatory guidelines and professional counsel for specific advice.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07263815?term=medical+device